Ferrata Storti Foundation

SHERPA: Unknown

People

  1. Tallman
    Tallman
  2. Levine
    Levine
  3. Zelenetz
    Zelenetz
  4. Mauro
    Mauro
  5. Stein
    Stein
  6. Abdel-Wahab
    Abdel-Wahab
  7. Dogan
    Dogan
  8. Horwitz
    Horwitz
  9. Perales
    Perales
  10. Salles
    Salles

Groups

  1. Department of Medicine (295)
  2. Hematologic Malignancies, Division of (294)
  3. Center for Hematologic Malignancies (270)
  4. Adult Leukemia (107)
  5. Lymphoma (73)
  6. GSK Faculty (70)
  7. Executive Committee, Center for Hematologic Malignancies (60)
  8. Hematologic Malignancies Research (45)
  9. Sloan Kettering Institute Postdocs (43)
  10. Center for Molecular Imaging and Biotechnology (CMIB) (41)
Search Within
Formats
  1. Meeting Abstract (178)
  2. Journal Article (122)
  3. Research Letter (26)
  4. Editorial (16)
  5. Review (11)
  6. Correspondence (1)
  7. Guidelines (1)
Groups
  1. Department of Medicine (295)
  2. Hematologic Malignancies, Division of (294)
  3. Center for Hematologic Malignancies (270)
  4. Adult Leukemia (107)
  5. Lymphoma (73)
  6. GSK Faculty (70)

More Groups

People
  1. Carl Landgren (25)
  2. Martin Tallman (25)
  3. Andrew Zelenetz (24)
  4. Ross Levine (24)
  5. Michael Mauro (21)
  6. Anas Younes (16)

More People

Years
  1. 2025 (15)
  2. 2024 (23)
  3. 2023 (17)
  4. 2022 (20)
  5. 2021 (13)
  6. 2020 (18)

More Years

Publications
  1. Haematologica (351)
  2. Haematologica Meeting Reports (4)

Results (355)


Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • Sgn-CD33A in combination with hypomethylating agents: A novel, well-tolerated regimen with high remission rate in older patients with AML
    Meeting Abstract

    Fathi, A.; Erba, H.; Lancet, J.; Stein, E.; Ravandi, F.; Faderl, S.; Walter, R.; Advani, A.; DeAngelo, D.; Kovacsovics, T.; more...
    Haematologica (2016)

    Fulltext@MSK | Save
  • Safety, efficacy and immune effects of venetoclax 400 mg daily in patients (pts) with relapsed chronic lymphocytic leukemia (CLL)
    Meeting Abstract

    Anderson, M. A.; Roberts, A. W.; Seymour, J. F.; Gerecitano, J. F.; Kahl, B. S.; Kipps, T. J.; Pagel, J. M.; Puvvada, S. D.; Wierda, W. G.; Gressick, L.; more...
    Haematologica (2016)

    Fulltext@MSK | Save
  • Checkmate 205: A phase 2 study of nivolumab in patients with classical Hodgkin lymphoma following autologous stem cell transplantation and brentuximab vedotin
    Meeting Abstract

    Engert, A.; Santoro, A.; Shipp, M.; Zinzani, P. L.; Timmerman, J.; Ansell, S.; Armand, P.; Fanale, M.; Ratanatharathorn, V.; Kuruvilla, J.; more...
    Haematologica (2016)

    Fulltext@MSK | Save
  • Multicohort phase 2 study of pembrolizumab for relapsed/refractory classical Hodgkin lymphoma (R/R cHL): Keynote-087
    Meeting Abstract

    Moskowitz, C.; Zinzani, P. L.; Fanale, M. A.; Armand, P.; Johnson, N.; Ribrag, V.; Radford, J.; von Tresckow, B.; Tomita, A.; Shipp, M. A.; more...
    Haematologica (2016)

    Fulltext@MSK | Save
  • Phase 1 trial of CUDC-907, a novel, oral dual inhibitor of HDAC and Pi3k: Updated assessment of patients with relapsed or refractory diffuse large B-cell lymphoma, including double expressor lymphoma
    Meeting Abstract

    Younes, A.; Berdeja, J.; Patel, M.; Kelly, K.; Flinn, I.; Gerecitano, J.; Neelapu, S.; Copeland, A.; Wang, J.; Gong, L.; more...
    Haematologica (2016)

    Fulltext@MSK | Save
  • Management of transaminase elevations associated with idelalisib
    Meeting Abstract

    Ghia, P.; Coutre, S.; Flinn, I. W.; Gopal, A. K.; O'Brien, S. M.; Salles, G. A.; Newcomb, T.; Waldapfel, C. C.; Ye, W.; Zelenetz, A. D.; more...
    Haematologica (2016)

    Fulltext@MSK | Save
  • Updated data from a phase II dose finding trial of single agent isatuximab (SAR650984, Anti-CD38 Mab) in relapsed/refractory multiple myeloma (RRMM)
    Meeting Abstract

    Vij, R.; Martin, T.; Richter, J.; Cole, C.; Atanackovic, D.; Zonder, J.; Kaufman, J.; Mikhael, J.; Bensinger, W.; Dimopoulos, M.; more...
    Haematologica (2016)

    Fulltext@MSK | Save
  • A phase IB dose-escalation trial of isatuximab (SAR650984, anti-CD38 MAB) plus lenalidomide and dexamethasone in relapsed/refractory multiple myeloma (RRMM): Interim results from 2 new dose cohorts
    Meeting Abstract

    Lendvai, N.; Vij, R.; Martin, T. G.; Baz, R.; Campana, F.; Mazuir, F.; Charpentier, E.; Benson, D. M.
    Haematologica (2016)

    Fulltext@MSK | Save
  • A phase IB study evaluating the safety and clinical activity of atezolizumab combined with obinutuzumab in patients with relapsed or refractory non-Hodgkin lymphoma
    Meeting Abstract

    Palomba, M. L.; Till, B. G.; Park, S. I.; Morschhauser, F.; Cartron, G.; Marks, R.; Penuel, E.; Chitra, S.; Byon, J. C. H.; Popplewell, L.
    Haematologica (2016)

    Fulltext@MSK | Save
  • High hemoglobin concentrations and risk of thrombosis: Causality or confounding?
    Meeting Abstract

    Rognvaldsson, S.; Lund, S. H.; Hultcrantz, M.; Eiriksdottir, G.; Harris, T. B.; Gudnason, V.; Kristinsson, S. Y.
    Haematologica (2016)

    Fulltext@MSK | Save

    • Ferrata Storti Foundation – authorized name for: